{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:10:08Z","timestamp":1789053008440,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research Programs of Sichuan Provincial Cadre Healthcare Commission","award":["2022-1501"],"award-info":[{"award-number":["2022-1501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00406-026-02353-4","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:32:15Z","timestamp":1787387535000},"page":"3329-3341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of blood p-tau subtypes in Alzheimer\u2019s disease progression and pathology: systematic review and meta-analysis"],"prefix":"10.1007","volume":"276","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoshu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"2","key":"2353_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Estimation of the global prevalence of dementia","year":"2022","unstructured":"Estimation of the global prevalence of dementia (2022) in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105\u2013e25","journal-title":"Lancet Public Health"},{"issue":"2","key":"2353_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"JC Morris","year":"2001","unstructured":"Morris JC, Price JL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer\u2019s disease. J Mol Neurosci 17(2):101\u2013118","journal-title":"J Mol Neurosci"},{"issue":"2","key":"2353_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal DR, Walter J, Saido TC et al (2015) Neuropathology and biochemistry of A\u03b2 and its aggregates in Alzheimer\u2019s disease. Acta Neuropathol 129(2):167\u2013182","journal-title":"Acta Neuropathol"},{"issue":"Suppl 3","key":"2353_CR4","first-page":"8","volume":"67","author":"PM Aupperle","year":"2006","unstructured":"Aupperle PM (2006) Navigating patients and caregivers through the course of Alzheimer\u2019s disease. J Clin Psychiatry 67(Suppl 3):8\u201314 quiz 23","journal-title":"J Clin Psychiatry"},{"issue":"Pt 5","key":"2353_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/awt062","volume":"136","author":"SE Lesn\u00e9","year":"2013","unstructured":"Lesn\u00e9 SE, Sherman MA, Grant M et al (2013) Brain amyloid-\u03b2 oligomers in ageing and Alzheimer\u2019s disease. Brain 136(Pt 5):1383\u20131398","journal-title":"Brain"},{"issue":"2","key":"2353_CR6","doi-asserted-by":"publisher","first-page":"e14508","DOI":"10.1002\/alz.14508","volume":"21","author":"NJ Ashton","year":"2025","unstructured":"Ashton NJ, Keshavan A, Brum WS et al (2025) The Alzheimer\u2019s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. Alzheimers Dement 21(2):e14508","journal-title":"Alzheimers Dement"},{"issue":"10468","key":"2353_CR7","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","volume":"404","author":"MT Heneka","year":"2024","unstructured":"Heneka MT, Morgan D, Jessen F (2024) Passive anti-amyloid \u03b2 immunotherapy in Alzheimer\u2019s disease-opportunities and challenges. Lancet 404(10468):2198\u20132208","journal-title":"Lancet"},{"issue":"9","key":"2353_CR8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","volume":"9","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Sch\u00f6ll M, Strandberg O et al (2017) (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer\u2019s disease. EMBO Mol Med 9(9):1212\u20131223","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2353_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS et al (2023) Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener 18(1):18","journal-title":"Mol Neurodegener"},{"issue":"7","key":"2353_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15(7):673\u2013684","journal-title":"Lancet Neurol"},{"issue":"4","key":"2353_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaneurol.2019.4749","volume":"77","author":"PF Meyer","year":"2020","unstructured":"Meyer PF, Pichet Binette A, Gonneaud J et al (2020) Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol 77(4):508\u2013516","journal-title":"JAMA Neurol"},{"issue":"11","key":"2353_CR12","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C et al (2023) Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement 19(11):4967\u20134977","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2353_CR13","doi-asserted-by":"publisher","first-page":"e14565","DOI":"10.1002\/alz.14565","volume":"21","author":"YS Lin","year":"2025","unstructured":"Lin YS, Kwon HS, Lee WJ et al (2025) Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: an East Asian study in Taiwan and Korea. Alzheimers Dement 21(1):e14565","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2353_CR14","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alz.13539","volume":"20","author":"PM Cogswell","year":"2024","unstructured":"Cogswell PM, Lundt ES, Therneau TM et al (2024) Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Alzheimers Dement 20(2):1225\u20131238","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2353_CR15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A et al (2024) Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol 271(4):2053\u20132066","journal-title":"J Neurol"},{"issue":"1","key":"2353_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","volume":"17","author":"ME Murray","year":"2022","unstructured":"Murray ME, Moloney CM, Kouri N et al (2022) Global neuropathologic severity of Alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Mol Neurodegener 17(1):85","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2353_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13195-024-01619-0","volume":"16","author":"M Budak","year":"2024","unstructured":"Budak M, Fausto BA, Osiecka Z et al (2024) Elevated plasma p-tau231 is associated with reduced generalization and medial temporal lobe dynamic network flexibility among healthy older African Americans. Alzheimers Res Ther 16(1):253","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"2353_CR18","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/brain\/awaf033","volume":"148","author":"J Fern\u00e1ndez Arias","year":"2025","unstructured":"Fern\u00e1ndez Arias J, Brum WS, Salvad\u00f3 G et al (2025) Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer\u2019s disease spectrum. Brain 148(7):2384\u20132399","journal-title":"Brain"},{"issue":"1","key":"2353_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S et al (2021) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging 1(1):114\u2013123","journal-title":"Nat Aging"},{"issue":"9","key":"2353_CR20","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1002\/alz.14087","volume":"20","author":"T Dayarathna","year":"2024","unstructured":"Dayarathna T, Roseborough AD, Gomes J et al (2024) Nanoscale flow cytometry-based quantification of blood-based extracellular vesicle biomarkers distinguishes MCI and Alzheimer\u2019s disease. Alzheimers Dement 20(9):6094\u20136106","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2353_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS et al (2021) Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement 17(8):1353\u20131364","journal-title":"Alzheimers Dement"},{"key":"2353_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"8","key":"2353_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529\u2013536","journal-title":"Ann Intern Med"},{"key":"2353_CR24","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"issue":"11","key":"2353_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"9","key":"2353_CR26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","volume":"58","author":"JJ Deeks","year":"2005","unstructured":"Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58(9):882\u2013893","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2353_CR27","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","volume":"15","author":"PR Kac","year":"2024","unstructured":"Kac PR, Gonz\u00e1lez-Ortiz F, Emer\u0161i\u010d A et al (2024) Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology. Nat Commun 15(1):2615","journal-title":"Nat Commun"},{"issue":"14","key":"2353_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, Zetterberg H, Mattsson N et al (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85(14):1240\u20131249","journal-title":"Neurology"},{"issue":"1","key":"2353_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s40478-022-01458-w","volume":"10","author":"RB Mofrad","year":"2022","unstructured":"Mofrad RB, Del Campo M, Peeters CFW et al (2022) Plasma proteome profiling identifies changes associated to AD but not to FTD. Acta Neuropathol Commun 10(1):148","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"2353_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","volume":"11","author":"SE O\u2019Bryant","year":"2015","unstructured":"O\u2019Bryant SE, Gupta V, Henriksen K et al (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research. Alzheimers Dement 11(5):549\u2013560","journal-title":"Alzheimers Dement"},{"key":"2353_CR31","doi-asserted-by":"publisher","first-page":"103837","DOI":"10.1016\/j.ebiom.2022.103837","volume":"76","author":"C Tissot","year":"2022","unstructured":"Tissot C, Therriault J, Kunach P et al (2022) Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET. EBioMedicine 76:103837","journal-title":"EBioMedicine"},{"issue":"1","key":"2353_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-021-00234-5","volume":"10","author":"X Ding","year":"2021","unstructured":"Ding X, Zhang S, Jiang L et al (2021) Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: a systematic review and meta-analysis. Transl Neurodegener 10(1):10","journal-title":"Transl Neurodegener"},{"issue":"3","key":"2353_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s00415-025-12996-3","volume":"272","author":"A Antonioni","year":"2025","unstructured":"Antonioni A, Raho EM, Di Lorenzo F et al (2025) Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer\u2019s disease continuum. A systematic review and meta-analysis. J Neurol 272(3):252","journal-title":"J Neurol"},{"issue":"2","key":"2353_CR34","doi-asserted-by":"publisher","first-page":"e14430","DOI":"10.1002\/alz.14430","volume":"21","author":"M Olvera-Rojas","year":"2025","unstructured":"Olvera-Rojas M, Sewell KR, Karikari TK et al (2025) Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/A\u03b242. Alzheimers Dement 21(2):e14430","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2353_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-023-02660-3","volume":"147","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya L, Alosco ML, Yhang E et al (2023) Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathol 147(1):5","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2353_CR36","doi-asserted-by":"publisher","first-page":"e14609","DOI":"10.1002\/alz.14609","volume":"21","author":"F Anastasi","year":"2025","unstructured":"Anastasi F, Fern\u00e1ndez-Lebrero A, Ashton NJ et al (2025) A head-to-head comparison of plasma biomarkers to detect Alzheimer\u2019s disease in a memory clinic. Alzheimers Dement 21(2):e14609","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2353_CR37","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601","journal-title":"Brain"},{"issue":"1","key":"2353_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S et al (2024) Diagnostic performance of plasma pTau(217), pTau(181), A\u03b2(1\u201342) and A\u03b2(1\u201340) in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther 16(1):139","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"2353_CR39","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1002\/alz.14084","volume":"20","author":"X Yu","year":"2024","unstructured":"Yu X, Shi R, Zhou X et al (2024) Correlations between plasma markers and brain A\u03b2 deposition across the AD continuum: evidence from SILCODE. Alzheimers Dement 20(9):6170\u20136182","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2353_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","volume":"12","author":"T Guo","year":"2020","unstructured":"Guo T, Korman D, La Joie R et al (2020) Normalization of CSF pTau measurement by A\u03b2(40) improves its performance as a biomarker of Alzheimer\u2019s disease. Alzheimers Res Ther 12(1):97","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2353_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00401-024-02744-8","volume":"147","author":"M Thierry","year":"2024","unstructured":"Thierry M, Ponce J, Mart\u00e0-Ariza M et al (2024) The influence of APOE(\u03b54) on the pTau interactome in sporadic Alzheimer\u2019s disease. Acta Neuropathol 147(1):91","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2353_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12974-022-02567-y","volume":"19","author":"Y Dong","year":"2022","unstructured":"Dong Y, Yu H, Li X et al (2022) Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer\u2019s disease. J Neuroinflammation 19(1):205","journal-title":"J Neuroinflammation"},{"issue":"15","key":"2353_CR43","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1212\/WNL.0000000000200953","volume":"99","author":"BD Greenberg","year":"2022","unstructured":"Greenberg BD, Pettigrew C, Soldan A et al (2022) CSF Alzheimer disease biomarkers: time-varying relationships with MCI symptom onset and associations with age, sex, and ApoE4. Neurology 99(15):e1640\u2013e50","journal-title":"Neurology"},{"issue":"3","key":"2353_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/JAD-2009-0999","volume":"16","author":"MI Kester","year":"2009","unstructured":"Kester MI, Blankenstein MA, Bouwman FH et al (2009) CSF biomarkers in Alzheimer\u2019s disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 16(3):601\u2013607","journal-title":"J Alzheimers Dis"},{"key":"2353_CR45","doi-asserted-by":"publisher","first-page":"101446","DOI":"10.1016\/j.arr.2021.101446","volume":"71","author":"YR Chen","year":"2021","unstructured":"Chen YR, Liang CS, Chu H et al (2021) Diagnostic accuracy of blood biomarkers for Alzheimer\u2019s disease and amnestic mild cognitive impairment: a meta-analysis. Ageing Res Rev 71:101446","journal-title":"Ageing Res Rev"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02353-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02353-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02353-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:49:06Z","timestamp":1789051746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02353-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2353"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02353-4","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. The authors of this manuscript declare no relationships with any companies, whose products or services may be.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Human ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}